Wave Life Sciences will use Deep Genomics’ machine learning-driven biomedical platform to discover novel therapies for treating genetic neuromuscular disorders. Wave is already assessing a Duchenne muscular dystrophy (pictured) candidate in a gklobal Phase I study.[Courtney Young